Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
July 17, 2024 07:15 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
July 14, 2024 21:46 ET
|
Opthea Limited
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024 Retail Entitlement Offer follows...
Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD
July 09, 2024 07:30 ET
|
Opthea Limited
Research underpins sozinibercept’s potential as novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina Published in peer-reviewed journal...
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
June 18, 2024 20:57 ET
|
Opthea Limited
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m1) will close at 5:00 pm...
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
June 13, 2024 19:58 ET
|
Opthea Limited
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m1) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024 MELBOURNE,...
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
June 11, 2024 21:13 ET
|
Opthea Limited
Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2...
Opthea To Present at Clinical Trials at the Summit Meeting
June 03, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
May 28, 2024 07:30 ET
|
Opthea Limited
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials...
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
May 01, 2024 07:30 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
Opthea to Present at the OIS Retina Innovation Summit at ARVO
April 25, 2024 09:00 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...